{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:19:48Z","timestamp":1790011188025,"version":"4.0.1"},"reference-count":13,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n \n Atopic dermatitis (\n AD<\/jats:styled-content>\n ) is a chronic inflammatory skin disease characterised by epidermal barrier dysfunction and type 2 immune dysregulation. Dupilumab was the first biologic approved for severe\n AD<\/jats:styled-content>\n and has transformed management of moderate\u2010to\u2010severe disease. Although clinical trials and international real\u2010world studies have demonstrated sustained efficacy and acceptable tolerability, Australian data describing patient\u2010reported experience with dupilumab remain limited.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We conducted a cross\u2010sectional survey study of adults receiving dupilumab for moderate\u2010to\u2010severe AD at the Royal Melbourne Hospital dermatology clinic. Over a two\u2010month period, QR codes linked to an anonymous electronic questionnaire displayed in waiting areas and consultation rooms. Survey data were collected and managed using REDCap (Research Electronic Data Capture). The questionnaire examined treatment administration, perceived effectiveness, symptom change, treatment satisfaction, ocular and non\u2010ocular adverse effects and concomitant therapy use.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n During the recruitment period, 68 patients receiving dupilumab attended clinic and were eligible to participate; 48 completed the survey, corresponding to a response rate of 70.6%. Most respondents reported marked clinical benefit, with 66.7% reporting significant improvement in eczema control and 22.9% reporting complete resolution. Overall satisfaction was high, with 83.3% reporting being satisfied or very satisfied with treatment. Dupilumab was perceived as more effective than previous therapies by 83.3% of patients. Ocular symptoms were common amongst the cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In this tertiary australian cohort, patients treated with dupilumab reported high satisfaction and Substantial improvement in disease control and quality of life. These findings support the real\u2010world effectiveness of dupilumab and highlight the importance of proactive recognition and management of ocular adverse effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ajd.70193","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:14:01Z","timestamp":1787289241000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient Perspectives on Dupilumab Therapy for Atopic Dermatitis: Experiences, Expectations and Treatment Impact"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9119-4896","authenticated-orcid":false,"given":"Nadine","family":"Abu\u2010Ghazaleh","sequence":"first","affiliation":[{"name":"Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5750-1920","authenticated-orcid":false,"given":"Gayle","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia"},{"name":"Department of Medicine University of Medicine Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Dermatology Royal Melbourne Hospital Parkville Victoria Australia"},{"name":"Department of Medicine University of Medicine Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"10023","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic Dermatitis","volume":"387","author":"Weidinger S.","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public Health Burden and Epidemiology of Atopic Dermatitis","volume":"35","author":"Silverberg J. I.","year":"2017","journal-title":"Dermatologic Clinics"},{"issue":"1","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab Progressively Improves Systemic and Cutaneous Abnormalities in Patients With Atopic Dermatitis","volume":"143","author":"Guttman\u2010Yassky E.","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"24","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab Versus Placebo in Atopic Dermatitis","volume":"375","author":"Simpson E. L.","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10086","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long\u2010Term Management of Moderate\u2010To\u2010Severe Atopic Dermatitis With Dupilumab and Concomitant Topical Corticosteroids (LIBERTY AD CHRONOS): A 1\u2010Year, Randomised, Double\u2010Blinded, Placebo\u2010Controlled, Phase 3 Trial","volume":"389","author":"Blauvelt A.","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","article-title":"Dupilumab Drug Survival and Associated Predictors in Patients With Moderate\u2010To\u2010Severe Atopic Dermatitis: Long\u2010Term Results From the BioDay Registry","volume":"158","author":"Spekhorst L. S.","year":"2022","journal-title":"JAMA Dermatology"},{"issue":"6","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bjd.21794","article-title":"Real\u2010World Data on the Effectiveness, Safety and Drug Survival of Dupilumab: An Analysis From the TREATgermany Registry","volume":"187","author":"St\u00f6lzl D.","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"e_1_2_11_9_1","first-page":"e6","article-title":"Dupilumab\u2010Associated Ocular Surface Disease","volume":"63","author":"Foley P.","year":"2022","journal-title":"Australasian Journal of Dermatology"},{"key":"e_1_2_11_10_1","first-page":"1","article-title":"Dupilumab\u2010Associated Ocular Surface Disease","volume":"225","author":"Bohner A.","year":"2021","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"e_1_2_11_11_1","first-page":"2231","article-title":"Dupilumab\u2010Associated Ocular Surface Disease","volume":"35","author":"Popiela M. Z.","year":"2021","journal-title":"Eye"},{"issue":"6","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/bjd\/ljae344","article-title":"An Expert Consensus on Managing Dupilumab\u2010Related Ocular Surface Disorders in People With Atopic Dermatitis","volume":"191","author":"Ardern\u2010Jones M. R.","year":"2024","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014A Metadata\u2010Driven Methodology and Workflow Process for Providing Translational Research Informatics Support","volume":"42","author":"Harris P. A.","year":"2009","journal-title":"Journal of Biomedical Informatics"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: Building an International Community of Software Platform Partners","volume":"95","author":"Harris P. A.","year":"2019","journal-title":"Journal of Biomedical Informatics"}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajd.70193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.70193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:14:04Z","timestamp":1787289244000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.70193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":13,"alternative-id":["10.1111\/ajd.70193"],"URL":"https:\/\/doi.org\/10.1111\/ajd.70193","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"2026-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajd.70193"}}